Company
Endo
Endo has 18 drugs tracked on RxWires: 6 post-market, 7 in Phase 3, 2 in Phase 2/3, 1 in Phase 2, 1 in Phase 1/2, 1 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| CCH-aaes | Post-Market | Edematous Fibrosclerotic Panniculopathy (EFP) |
| Testosterone Gel | Post-Market | Low Testosterone |
| lidocaine | Post-Market | Low Back Pain |
| Qwo | Post-Market | Cellulite |
| Lidoderm | Post-Market | Diabetes |
| topiramate | Post-Market | Migraine |
| Frovatriptan 2.5 mg | Phase 3 | Migraine |
| Oxymorphone ER | Phase 3 | Chronic Pain |
| EN3835 | Phase 3 | Edematous Fibrosclerotic Panniculopathy (Cellulite) |
| AA4500 | Phase 3 | Peyronie's Disease |
| collagenase clostridium histolyticum | Phase 3 | Dupuytren's Disease |
| Octreotide | Phase 3 | Acromegaly |
| EN3285 | Phase 3 | Oral Mucositis |
| Skin biopsy | Phase 2/3 | Diabetic Peripheral Neuropathy |
| Valrubicin, 800 mg | Phase 2/3 | Carcinoma in Situ |
| Cabozantinib | Phase 2 | Differentiated Thyroid Cancer |
| Trifluridine/tipiracil chemoradiation | Phase 1/2 | Locally Advanced Rectal Cancer |
| propofol | Phase 1 | General Anesthesia |
Latest
No recent events.
Follow Endo on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.